American Society of Hirudotherapy

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy

Clinical practice guidelines published in Blood advances (2018)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Practice guidelineDrug DevelopmentSalivary PharmacologyBates et al. · Blood advances, 2018

Abstract

BACKGROUND: Venous thromboembolism (VTE) complicates ∼1.2 of every 1000 deliveries. Despite these low absolute risks, pregnancy-associated VTE is a leading cause of maternal morbidity and mortality. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and others in decisions about the prevention and management of pregnancy-associated VTE. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations. RESULTS: The panel agreed on 31 recommendations related to the treatment of VTE and superficial vein thrombosis, diagnosis of VTE, and thrombosis prophylaxis. CONCLUSIONS: There was a strong recommendation for low-molecular-weight heparin (LWMH) over unfractionated heparin for acute VTE. Most recommendations were conditional, including those for either twice-per-day or once-per-day LMWH dosing for the treatment of acute VTE and initial outpatient therapy over hospital admission with low-risk acute VTE, as well as against routine anti-factor Xa (FXa) monitoring to guide dosing with LMWH for VTE treatment. There was a strong recommendation (low certainty in evidence) for antepartum anticoagulant prophylaxis with a history of unprovoked or hormonally associated VTE and a conditional recommendation against antepartum anticoagulant prophylaxis with prior VTE associated with a resolved nonhormonal provoking risk factor.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticlePractice Guideline
Indexed MeSH termsAdministration, OralAnticoagulantsBreast FeedingEvidence-Based MedicineFemaleFibrinolytic AgentsHeparin, Low-Molecular-WeightHumansInfantInfant, NewbornPregnancyVenous Thromboembolism

Summary

These ASH evidence-based guidelines give 31 recommendations on pregnancy-associated VTE, strongly recommending low-molecular-weight heparin over unfractionated heparin for acute VTE, and conditionally recommending against routine anti-factor Xa monitoring and against antepartum prophylaxis after VTE with a resolved nonhormonal provoking risk factor.

Context

This ASH guideline, developed by a multidisciplinary panel using the GRADE approach, provides 31 recommendations for the prevention and management of pregnancy-associated VTE, including a strong recommendation for low-molecular-weight heparin over unfractionated heparin for acute VTE, with most recommendations being conditional. For hirudotherapy, the guideline serves as a contemporary benchmark for anticoagulation standards in a high-risk population, situating leech-derived anticoagulants such as hirudin and its analogs (lepirudin, desirudin, bivalirudin) within the broader therapeutic landscape clinicians navigate. An honest caveat is that the guideline focuses specifically on heparin-based agents and does not evaluate or recommend direct thrombin inhibitors derived from the leech secretome; thus, it informs context rather than directly validating hirudin-based therapy in pregnancy.

Citation

Reference (Vancouver style)

Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA, James AH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802. PMID: 30482767

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.